We are live on !
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
Turnover
60.61%
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$2.99M
Cap. Flow % of AUM
Cap. Flow %
4.5%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.45% |
| 2 | Miscellaneous | 41.8% |
| 3 | Consumer Discretionary | 7.1% |
| 4 | Consumer Staples | 6.25% |
| 5 | Communication Services | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
CALL
Coca-Cola
KO
$399B
| $15K | 0.02% |
54,200
-75,800
| -58% | -$3.45M |
2016 Q1
6 quarters
|
|
177
CALL
Kroger
KR
$37.3B
| $15K | 0.02% |
64,200
+39,200
| +157% | +$883K |
2017 Q2
1 quarter
|
|
|
LJPC
178
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $15K | 0.02% |
+2,700
| New | +$86.8K |
2017 Q3
0 quarters
|
|
179
PUT
Walmart Inc
WMT
$939B
| $14K | 0.02% |
+15,000
| New | +$394K |
2017 Q3
0 quarters
|
|
180
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $14K | 0.02% |
+2,222
| New | +$170K |
2017 Q3
0 quarters
|
|
|
ARNA
181
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14K | 0.02% |
+10,000
| New | +$229K |
2017 Q3
0 quarters
|
|
|
TWX
182
PUT
DELISTED
Time Warner Inc
TWX
| $14K | 0.02% |
8,000
+4,000
| +100% | +$406K |
2016 Q2
5 quarters
|
|
183
PUT
Intuitive Surgical
ISRG
$155B
| $13K | 0.02% |
13,500
-63,900
| -83% | -$6.96M |
2017 Q1
2 quarters
|
|
184
CALL
Kimberly-Clark
KMB
$35.7B
| $12K | 0.02% |
15,700
+700
| +5% | +$85.5K |
2016 Q1
6 quarters
|
|
|
185
CALL
General Mills
GIS
$17.8B
| $10K | 0.02% |
108,600
-15,400
| -12% | -$844K |
2016 Q1
6 quarters
|
|
186
CALL
Monster Beverage
MNST
$92.1B
| $10K | 0.02% |
+40,000
| New | +$539K |
2017 Q3
0 quarters
|
|
187
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$821B
| $10K | 0.02% |
+25,000
| New | +$6.16M |
2017 Q3
0 quarters
|
|
188
CALL
AstraZeneca
AZN
$262B
| $9K | 0.01% |
23,700
-6,350
| -21% | -$401K |
2017 Q2
1 quarter
|
|
189
CALL
Clorox
CLX
$10.6B
| $9K | 0.01% |
22,000
-3,200
| -13% | -$430K |
2016 Q1
6 quarters
|
|
|
190
CALL
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
| $9K | 0.01% |
+20,000
| New | +$450K |
2017 Q3
0 quarters
|
|
|
POT
191
CALL
DELISTED
Potash Corp Of Saskatchewan
POT
| $9K | 0.01% |
5,000
-86,300
| -95% | -$1.54M |
2016 Q1
6 quarters
|
|
192
PUT
DexCom
DXCM
$32.4B
| $8K | 0.01% |
+40,000
| New | +$707K |
2017 Q3
0 quarters
|
|
193
CALL
PepsiCo
PEP
$183B
| $8K | 0.01% |
48,900
-7,500
| -13% | -$866K |
2015 Q4
7 quarters
|
|
194
CALL
Rocket Pharmaceuticals
RCKT
$260M
| $7K | 0.01% |
3,725
-23,650
| -86% | -$108K |
2017 Q2
1 quarter
|
|
195
PUT
Verizon
VZ
$185B
| $7K | 0.01% |
22,500
+7,500
| +50% | +$353K |
2015 Q4
7 quarters
|
|
|
ALXN
196
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $7K | 0.01% |
+5,600
| New | +$761K |
2017 Q3
0 quarters
|
|
197
PUT
uniQure
QURE
$1.53B
| $6K | 0.01% |
50,000
+46,000
| +1,150% | +$370K |
2017 Q2
1 quarter
|
|
198
PUT
TransDigm Group
TDG
$63.1B
| $5K | 0.01% |
10,700
| – | – |
2017 Q1
2 quarters
|
|
|
AIMT
199
PUT
DELISTED
Aimmune Therapeutics
AIMT
| $5K | 0.01% |
+16,000
| New | +$345K |
2017 Q3
0 quarters
|
|
200
Coca-Cola Europacific Partners
CCEP
$49.7B
| $4K | 0.01% |
+100
| New | +$4.24K |
2017 Q3
0 quarters
|
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.